anti-Amyloid beta (Abeta) Antibodies

Abeta encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Additionally we are shipping beta Amyloid Proteins (3) and beta Amyloid Kits (2) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
Abeta 351 P05067
Abeta 54226 P08592
Abeta 11820 P12023
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-beta Amyloid Antibodies at antibodies-online.com

Showing 10 out of 258 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Mouse Un-conjugated ELISA, ICC, IF, IHC, IHC (ff), IHC (p), IP, WB Immunocytochemistry/Immunofluorescence: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - Immunofluorescent detection of beta Amyloid with MOAB-2 in the subiculim of 1-, 2- and 4- month old 5xFAD mice. Scale bar 20 um (from PMID: 22423893). Immunohistochemistry: beta Amyloid Antibody (MOAB-2) [NBP2-13075] - IHC analysis of beta Amyloid on normal mouse brain (left) and 5xFAD mouse brain (right) using DAB with hematoxylin counterstain. The MOAB-2 antibody was used at 1:20 on normal mouse brain and at 1:400 on 5xFAD mouse brain. 0.1 mL Log in to see 7 to 9 Days
$516.98
Details
Human Rabbit Un-conjugated IHC, ELISA, WB 100 μg Log in to see 5 to 7 Days
$598.50
Details
Cow Rabbit Un-conjugated ELISA, ICC, IF, IHC, Act (ligand), WB Western Blot: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Lane 1-10: beta Amyloid pyro E3 peptide. Load: 1 ug per lane 1-2, 0.2 ug per lane 3-4, 0.05 ug per lane 5-6, 0.01 ug per lane 7-8, 0.005 ug per lane 9-10. Primary antibody: Beta Amyloid pyro E3 antibody at 0.5 ug/mL for overnight at 4C. Secondary antibody: IRDye800 rabbit secondary antibody at 1:10,000 for 45 min at RT. Block: 5% BLOTTO overnight at 4C. Predicted/Observed size: 86.9 kDa for beta Amyloid pyro E3 peptide. Cross reactivity with Beta Amyloid 3 peptide is >1000 fold below pyrE3 reactivity and contains no reactivity towards the Beta Amyloid 42 A beta peptide (data not shown). Immunocytochemistry/Immunofluorescence: beta Amyloid [Pyro Glu3] Antibody [NBP1-44048] - Laser scanning confocal microscopy was carried out using human tissue sections from frontal cortex. Figure A shows an example section that was immunostained for the presence of pyrE3Abeta (green). Figure B shows that the immunogen peptide completely blocked the NBP1-44048 antibody. 0.05 mg Log in to see 7 to 9 Days
$587.60
Details
Cow Rabbit Un-conjugated WB Western blot analysis of Beta Amyloid expression in HEK293T (A), Hela (B) whole cell lysates. 200 μL Log in to see 13 to 14 Days
$487.50
Details
Chicken Rabbit Un-conjugated IHC, WB Immunohistochemical analysis of Beta Amyloid (pT743) staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0). The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. Western blot analysis of Beta Amyloid (pT743) expression in MCF7 colchicine-treated (A), mouse liver (B), PC12 (C) whole cell lysates. 200 μL Log in to see 13 to 14 Days
$575.00
Details
Human Mouse Un-conjugated ELISA, IF, WB Fluorescent microscopy image (appotome) of 6 months-old APP/PS1 mouse hypocampus and somatosensory cortex. Double staining: in blue, nuclei DAPI staining. In red, Amyloid plaques. Immunofluorescence slices with the anti-amyloid beta antibody from different mouse genotypes. Wild type (WT), APP/PS1 and APP KO. In red, amyloid plaques. 100 μg Log in to see 6 to 7 Days
$336.85
Details
Human Rabbit Un-conjugated WB Western blot analysis of Beta Amyloid expression in mouse kidney (A), mouse heart (B) whole cell lysates. 200 μL Log in to see 13 to 14 Days
$487.50
Details
Human Rabbit Un-conjugated EIA, IF, IHC (p), WB 0.1 mg Log in to see 6 to 8 Days
$594.00
Details
Human Rabbit Un-conjugated ELISA, IHC, IHC (p), WB Immunohistochemistry: beta Amyloid Antibody [NBP2-25093] - Analysis of APP in human brain tissue with APP antibody at 2.5 ug/ml. Immunohistochemistry-Paraffin: beta Amyloid Antibody [NBP2-25093] - Human brain (Alzheimer's disease) tissue with APP antibody at 10 ug/mL. 0.1 mg Log in to see 8 to 11 Days
$488.73
Details
Human Rabbit Un-conjugated ICC, IF, IHC (p), IHC, WB Western Blot: beta Amyloid Antibody [NBP1-32081] - Sample(30 ug of whole cell lysate)A:Hep G2 7. 5% SDS PAGE, antibody diluted at 1:1500. 0.1 mL Log in to see 8 to 11 Days
$516.98
Details

Top referenced anti-beta Amyloid Antibodies

  1. Human Monoclonal beta Amyloid Primary Antibody for ELISA, ICC - ABIN4284085 : Youmans, Tai, Kanekiyo, Stine, Michon, Nwabuisi-Heath, Manelli, Fu, Riordan, Eimer, Binder, Bu, Yu, Hartley, LaDu: Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody. in Molecular neurodegeneration 2012 (PubMed)
    Show all 10 Pubmed References

  2. Cow (Bovine) Polyclonal beta Amyloid Primary Antibody for ELISA, ICC - ABIN4284076 : He, Barrow: The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. in Biochemistry 1999 (PubMed)
    Show all 4 Pubmed References

  3. Human Monoclonal beta Amyloid Primary Antibody for ELISA, IF - ABIN5508784 : Markoutsa, Papadia, Clemente, Flores, Antimisiaris: Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells. in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2012 (PubMed)
    Show all 4 Pubmed References

  4. Human beta Amyloid Primary Antibody for ELISA (Capture), IF - ABIN1110165 : Levites, Jansen, Smithson, Dakin, Holloway, Das, Golde et al.: Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor ... in The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 (PubMed)
    Show all 3 Pubmed References

  5. Fruit Fly (Drosophila melanogaster) Polyclonal beta Amyloid Primary Antibody for ELISA, ICC - ABIN4284077 : Youssef, Florent-Béchard, Malaplate-Armand, Koziel, Bihain, Olivier, Leininger-Muller, Kriem, Oster, Pillot: N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis. in Neurobiology of aging 2008 (PubMed)
    Show all 3 Pubmed References

  6. Human beta Amyloid Primary Antibody for ELISA (Capture), ELISA (Detection) - ABIN1110166 : Levites, Das, Price, Rochette, Kostura, McGowan, Murphy, Golde: Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. in The Journal of clinical investigation 2006 (PubMed)
    Show all 2 Pubmed References

  7. Human beta Amyloid Primary Antibody for IF, IP - ABIN1110164 : Levites, Smithson, Price, Dakin, Yuan, Sierks, Kim, McGowan, Reed, Rosenberry, Das, Golde: Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006 (PubMed)
    Show all 2 Pubmed References

  8. Human Polyclonal beta Amyloid Primary Antibody for IHC (fro), IHC (p) - ABIN2477631 : Romaguera, Grimalt, Vilaplana: Eczematous and purpuric allergic contact dermatitis from boots. in Contact dermatitis 1990 (PubMed)
    Show all 3 Pubmed References

  9. Human Polyclonal beta Amyloid Primary Antibody for ELISA, WB - ABIN1573928 : Jia, Liu, Song, Pan, Chen, Cui, Wang: Berberine suppresses amyloid-beta-induced inflammatory response in microglia by inhibiting nuclear factor-kappaB and mitogen-activated protein kinase signalling pathways. in The Journal of pharmacy and pharmacology 2012 (PubMed)

More Antibodies against beta Amyloid Interaction Partners

Human Amyloid beta (Abeta) interaction partners

  1. Identified TMEM30A as a candidate partner for beta-carboxyl-terminal fragment (betaCTF) of amyloid-beta precursor protein (APP). TMEM30A physically interacts with betaCTF in endosomes and may impair vesicular traffic, leading to abnormally enlarged endosomes. Data suggested that TMEM30A is involved in betaCTF-dependent endosome abnormalities that are related to Abeta overproduction

  2. ASIC1a modulates the ABETA-mediated increase in intrinsic excitability of CA1 pyramidal neurons. The study was performed on APP transgenic mice (Tg2576) expressing high levels of human mutant (K670N/M671L) APP transgene (hAPPK670N/M671L).

  3. For the first time, natural ABETA (1-42) fibrils (WT) implicated in Alzheimer's disease, as well as two synthetic mutants forming less toxic amyloid fibrils (L34T) and highly toxic oligomers (oG37C), are chemically characterized at the scale of a single structure using tip-enhanced Raman spectroscopy .

  4. Male heterozygous (HET) APP23 mice, overexpressing human APP 751 carrying the Swedish double mutation (K670M/N671L) were used for all experiments. The ABETA 1-42/ABETA 1-40 ratio spikes at 2 distinct ages: 1.5 months and 18 months. An initial build up in APP, C-terminal fragment beta and ABETA is observed at a young age. An increase in ABETA 1-42 at 18 months is followed by an increase in ABETA 1-40.

  5. This study shows by Atomic Force Microscopy that attachment of ApoE4/ABETA complexes to basement membrane laminin is significantly weaker than ApoE3/ABETA complexes.

  6. The pattern of development of cerebral amyloid angiopathy in the human brain suggests expansion of ABETA from the basement membranes to progressively replace all tissue elements in the artery wall.

  7. The purpose of this review article is to summarize recent research on how cerebral vascular ABETA and amyloid beta precursor protein influence cerebral hemostasis. [review]

  8. genetic manipulation of Sirt3 revealed that amyloid-beta increased levels of total tau acetylated tau through its modulation of Sirt3.

  9. brain. In the present study, two familial Ab42 mutations, namely A2V (harmful) and A2T (protective) have been analyzed and compared with the wild-type (WT) by performing all-atom molecular dynamics (MD) simulations in the absence and presence of curcumin, a well-known inhibitor of Abeta plaque formation. Mutant A2V was found to exhibit highest stability followed by WT and mutant A2T in the absence of curcumin

  10. These results provide evidence for an emerging role of BAG-1M in the regulation of BACE1 expression and AD pathogenesis and that targeting the BAG-1M-NF-kappaB complex may provide a mechanism for inhibiting Abeta production and plaque formation.

  11. A physical interaction between nicastrin (hNCT) and the gamma-secretase substrate amyloid beta-protein precursor (APPC100) confirmed the functionality of hNCT as a substrate recognizer.

  12. ethanol-induced eIF2alpha phosphorylation stimulates COX-2 expression and PGE2 production which induces the BACE1 expression and Abeta production via EP-2 receptor-dependent PKA/CREB pathway.

  13. Western diet (WD) dramatically increases ABETA levels and generates pyroglutamate-ABETA deposits.

  14. This study demonstrated that the APP21 transgenic rats develop age-dependent cognitive impairment and accelerated white matter inflammation.

  15. Data suggest that kinetics of degradation/proteolysis versus of aggregation of amyloid beta(1-40) and amyloid beta(1-42) at specific concentrations of amyloid beta, cathepsin B, and cystatin C can be modeled and predicted.

  16. In vitro neuroprotective effects of naringenin nanoemulsion against beta-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation.

  17. The results of study demonstrate that different degradation pathways play distinct roles in the removal of Abeta42 aggregates and in disease progression. These findings also suggest that pharmacologic treatments that are designed to stimulate cellular degradation pathways in patients with AD should be used with caution.

  18. This data demonstrates a specific function of APP or its metabolites is involved in the changes that occur during high fat diet-induced obesity.

  19. Our study provides new insights into the regulation of APP pre-mRNA processing, supports the role for nELAVLs as neuron-specific splicing regulators and reveals a novel function of AUF1 in alternative splicing.

  20. Data show that phospholipase D3 (PLD3) functions in endosomal protein sorting and plays an important role in regulating amyloid precursor protein (APP) processing.

Mouse (Murine) Amyloid beta (Abeta) interaction partners

  1. This study uncovered two clear phases in the life of APP23 mice: developmental and aging. Development displays similarities to young carriers of familial Alzheimer's disease (AD) mutations. All gene expression differences between APP23 and control mice correlate with aging. Age-related expression changes appear exacerbated/accelerated in APP23 mice.

  2. These results provide evidence for an emerging role of BAG-1M in the regulation of BACE1 expression and AD pathogenesis and that targeting the BAG-1M-NF-kappaB complex may provide a mechanism for inhibiting Abeta production and plaque formation.

  3. Conformational changes in a mouse model of Alzheimer's disease-linked amyloid beta and APP take place before the amyloids plaques can be seen.

  4. These results support the proposition that Aβ release during thrombosis serves as part of a natural defense against infection.

  5. These data suggest a novel regulatory function of juxta- and intra-membrane domains on the metabolism and function of APP.

  6. Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer-prone mice.

  7. pharmacological inhibition of PARP-1 reversed both particulate matter-induced Abeta increase and glial activation.

  8. The concentrations of Abeta (1-42) were also significantly higher in early stage Alzheimer's disease (AD) mice compared with WT mice, however, the levels were markedly lower compared with later stage AD mice, as determined by ELISA. In addition to increased levels of Abeta (1-42) in mice with later stage AD, reduced astrocyte staining was observed compared with WT mice.

  9. work expands the current knowledge regarding Abeta seeding and the consequences thereof and attributes microglia an important role in diminishing Abeta seeding by environmental enrichment.

  10. This study demonstrated that APP as a novel receptor for Slit ligand mediating axon guidance and neural circuit formation.

  11. In vivo, the NHE6 knockout (NHE6(KO)) mouse model showed elevated Abeta in the brain, consistent with a causal effect. Increased nuclear translocation of histone deacetylase 4 (HDAC4) in ApoE4 astrocytes, compared with the nonpathogenic ApoE3 allele, suggested a mechanistic basis for transcriptional down-regulation of NHE6.

  12. This commentary reviews the role of the Alzheimer amyloid peptide Abeta on basal synaptic transmission, synaptic short-term plasticity, as well as short- and long-term potentiation in transgenic mice, with a special focus on N-terminal truncated Abeta4-42.

  13. ADAP KO mice developed glomerular pathology. ADAP KO podocytes lack cell protrusions with actin cytoskeleton forming circumferential stress fibers.

  14. Therefore, APP modulates Nav1.6 sodium channels through a Go-coupled JNK pathway, which is dependent on phosphorylation of APP at Thr668.

  15. These findings suggest that in the absence of CLU, Abeta clearance shifts to perivascular drainage pathways, resulting in fewer parenchymal plaques but more CAA because of loss of CLU chaperone activity, complicating the potential therapeutic targeting of CLU for AD.

  16. Chronic Dyrk1 inhibition reversed cognitive deficits in Alzheimer's disease transgenic mice via reduction of APP and phosphorylated tau pathology.

  17. The findings provide a model for initiation of synaptic dysfunction whereby exposure to physiologic levels of amyloid beta for a prolonged period of time causes microstructural changes at the synapse which result in increased transmitter release, failure of synaptic plasticity, and memory loss.

  18. The results of the present study substantiate that cGMP has a role in the endocytic pathway of APP and suggest a scenario where the cyclic nucleotide enhances the production of Abeta by favoring the trafficking of APP from the cell cortex to the endolysosomal compartment.

  19. Study showed that the APP Osaka mutation has dual effects: it causes a loss-of-function of APP and gain-of-toxic-function of Abeta, though the latter seems to come out only after the former causes GABAergic depletion. Also present OSK-KI mice as a mouse model to replicate the hereditary form of recessive familial Alzheimer's disease.

  20. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity

beta Amyloid (Abeta) Antigen Profile

Protein Summary

This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene.

Gene names and symbols associated with anti-Amyloid beta (Abeta) Antibodies

  • amyloid beta precursor protein (APP) antibody
  • amyloid beta precursor protein (app) antibody
  • amyloid beta precursor protein (App) antibody
  • amyloid beta (A4) precursor protein (App) antibody
  • aaa antibody
  • Abeta antibody
  • Abpp antibody
  • ad1 antibody
  • Adap antibody
  • Ag antibody
  • appi antibody
  • betaApp antibody
  • ctfgamma antibody
  • Cvap antibody
  • E030013M08Rik antibody
  • PN-II antibody
  • pn2 antibody

Protein level used designations for anti-Amyloid beta (Abeta) Antibodies

alzheimer disease amyloid protein , amyloid beta A4 protein , beta-amyloid peptide , cerebral vascular amyloid peptide , peptidase nexin-II , preA4 , protease nexin-II , amyloid beta (A4) precursor protein (peptidase nexin-2, Alzheimer disease) , amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) , beta-amyloid precursor protein , alzheimer disease amyloid A4 protein homolog , amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) , ABPP , AG , amyloid A4 , amyloidogenic glycoprotein , appican , protease nexin II

GENE ID SPECIES
351 Homo sapiens
448208 Xenopus (Silurana) tropicalis
100427716 Macaca mulatta
54226 Rattus norvegicus
11820 Mus musculus
Selected quality suppliers for anti-beta Amyloid (Abeta) Antibodies
Did you look for something else?